Is there any reason to switch endocrine therapy after a patient undergoes bilateral oophorectomy?
This patient is a young lady with stage IV ER/PR positive, Her2 negative with oligometastatic breast cancer undergoing a planned bilateral oopherectomy due to an ovarian cyst and elevated CA 125. She is currently on tamoxifen and tolerating it well. Is there any data to suggest the patient should be switched to an AI or can be otherwise maintained on tamoxifen?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Utah Huntsman Cancer Institute
Answered on
In my opinion, in the absence of progressive disease, I would maintain this young woman on tamoxifen as long as there were not progressive disease and the tamoxifen was well tolerated.
Now that she has had an oophorectomy, and has been rendered menopausal, there will be many options when progressive...
Join for free or sign in to see the full answer